In a patient with bipolar II disorder who has worsening depression while on lamotrigine (Lamictal) 300 mg and is not taking any antipsychotic, what is the recommended next step in management?

Management of Worsening Depression in Bipolar II on Lamotrigine 300mg

Add an antidepressant (preferably an SSRI like fluoxetine) in combination with the existing lamotrigine, or consider adding lithium or quetiapine as augmentation strategies. The patient is already on an appropriate mood stabilizer (lamotrigine) at a therapeutic dose, so the next step is augmentation rather than switching.

Rationale for Augmentation Strategy

The WHO guidelines explicitly state that antidepressant medicines, always in combination with a mood stabilizer (lithium or valproate), may be considered in the treatment of moderate or severe depressive episodes of bipolar disorder, with SSRIs (fluoxetine) preferred over tricyclic antidepressants 1. Since this patient is already on lamotrigine 300mg (a mood stabilizer), adding an antidepressant is guideline-concordant.

Why Augmentation Over Switching

Lamotrigine has established efficacy in bipolar depression, particularly as add-on treatment. Recent meta-analyses demonstrate that lamotrigine as add-on treatment produces significantly greater decreases in depressive symptomatology compared to placebo (SMD -0.30, p = 0.004) 2. The patient is already at 300mg, which is within the therapeutic range, making augmentation the logical next step rather than abandoning an evidence-based foundation.

Specific Treatment Options (in order of preference)

First-Line Augmentation Options:

1. Add an SSRI (fluoxetine preferred): The WHO guidelines specifically recommend SSRIs over TCAs when antidepressants are used in bipolar depression 1. This should always be combined with the existing mood stabilizer (lamotrigine in this case).

2. Add lithium: Lithium combined with lamotrigine has demonstrated efficacy in bipolar depression 3, 4. The CANMAT/ISBD guidelines list "lurasidone plus lithium" and "lithium" as first-line options for bipolar I depression 3, and this combination strategy extends to bipolar II.

3. Add quetiapine: Quetiapine is consistently recommended as a first-line treatment for bipolar depression across guidelines 3, 5. It can be used as monotherapy or augmentation and has robust evidence for bipolar depression.

Alternative Considerations:

• Lithium + lamotrigine combination: This is specifically mentioned as effective for treatment-resistant bipolar depression 6, 7. If the patient doesn't respond to antidepressant augmentation, this combination should be the next step.

• Atypical antipsychotics: Aripiprazole or cariprazine can be considered as augmentation agents 7, though quetiapine has the strongest evidence base for bipolar depression specifically.

Critical Safety Considerations

Antidepressant-Induced Switch Risk

When adding an antidepressant, monitor closely for hypomanic symptoms. While the risk exists, antidepressants combined with mood stabilizers have lower switch rates than antidepressant monotherapy. The patient's existing lamotrigine provides some protection against mood destabilization.

Lamotrigine Dosing is Already Optimized

At 300mg, the patient is at the upper end of the typical therapeutic range (200-400mg for bipolar disorder). Do not increase lamotrigine further without first attempting augmentation, as higher doses increase rash risk without clear additional benefit 8.

Monitoring Requirements

• Assess for suicidal ideation: Bipolar depression carries high suicide risk 1
• Monitor for hypomanic/manic symptoms: Particularly in the first 2-8 weeks after adding an antidepressant
• Regular follow-up: Weekly for the first month, then biweekly

What NOT to Do

Do not use antidepressant monotherapy (i.e., don't stop the lamotrigine to start an antidepressant). This is explicitly contraindicated in bipolar depression and increases switch risk 1, 7.

Do not add valproate if considering future lamotrigine dose adjustments, as valproate increases lamotrigine levels more than 2-fold, requiring dose reduction 8.

Avoid tricyclic antidepressants and MAOIs initially, as they carry the highest risk for inducing mania 9.

Adjunctive Non-Pharmacological Options

Consider adding bright light therapy (BLT) as an adjunct. The 2025 ISBD guidelines recommend BLT for bipolar depression, with symptomatic remission expected by 4-6 weeks 10. Start with 15-30 minutes of morning exposure and titrate based on response. In bipolar II specifically, the hypomanic switch rate was 6% in controlled trials, with all symptoms resolving within 3 days of dose reduction 10.

Psychoeducation should be routinely offered to the patient and family members 1.

Algorithm Summary

1. Continue lamotrigine 300mg (do not stop or reduce)
2. Add SSRI (fluoxetine) OR add lithium OR add quetiapine
3. Monitor weekly × 4 weeks for response and switch symptoms
4. If partial response at 4-6 weeks: optimize dose of augmenting agent
5. If no response at 6-8 weeks: switch to lithium + lamotrigine combination or add quetiapine
6. Consider adjunctive bright light therapy throughout